retatrutide clinical data retatrutide vs Tirzepatide vs Semaglutide retatrutide clinical data FDA Approval

KEY OBSERVATIONS GLP-1 plans starting at just $69/mo are everywhere in Nooms advertising

The practical goal is to reduce avoidable contributors: titrate thoughtfully rather than racing to the highest dose, avoid unnecessarily rapid weight loss, prioritize adequate protein, perform resistance training to preserve lean tissue, and monitor for iron, zinc, vitamin D, vitamin B12, vitamin A, and other deficiencies when intake is substantially reduced

doi: 10.1097/JCMA.0000000000001254, 4

Other fronts are advancing quickly: Zepbound won FDA approval in 2024 for obstructive sleep apnea , and NIH-funded studies are testing GLP-1s for opioid use disorder